NIMML Institute and NImmune Biopharma have published case studies demonstrating how their TITAN-X AI platform has successfully identified novel therapeutic targets and accelerated drug development for inflammatory and autoimmune diseases.
Omilancor, a first-in-class oral LANCL2 agonist in Phase 3 development, demonstrated superior efficacy to anti-TL1A antibodies in treating inflammatory bowel disease with an unrivaled safety profile.